Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629307 | 0.94 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL629158 | 0.92 | MAPT (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL630000 | 0.92 | LTC4S (0.49) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL630571 | 0.91 | BCL6 (0.43) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL630256 | 0.90 | MAPK1 (0.46) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL629392 | 0.88 | MAPK1 (0.58) | SMN1; SMN2RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL629486 | 0.88 | LMNA (0.47) | ALDH1A1SMN1; SMN2RAB9AMAPTKMT2A | |
| SCHEMBL629866 | 0.85 | MAPK1 (0.45) | SMN1; SMN2KMT2AKDM4EMEN1LMNA | |
| SCHEMBL629127 | 0.84 | MAPK1 (0.54) | MAPK1NTRK1YES1PIM1AURKB | |
| SCHEMBL629472 | 0.84 | MAPT (0.50) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | claimed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | claimed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | NQO2, G6PD, GLS2 | ALDH1A1 440/4885SMN1; SMN2 4446/4885RAB9A 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.